OA23 Patient-reported outcome measure for giant cell arteritis: Cross-sectional validation study

Ndosi, Mwidimi; Almeida, Celia; Dawson, Jill; Dures, Emma; Greenwood, Rosemary; Guly, Catherine; Mackie, Sarah; Bromhead, Alison; Stern, Steve; Robson, Joanna C

doi:10.1093/rheumatology/keac132.023

All Outputs (3)

CO7 Patient reported outcome measure for giant cell arteritis: cross-sectional validation study (2022)
Journal Article
Ndosi, M., Almeida, C., Dawson, J., Dures, E., Greenwood, R., Guly, C., …Robson, J. (2022). CO7 Patient reported outcome measure for giant cell arteritis: cross-sectional validation study. Value in Health, 25(7, Supplement), Page S305. https://doi.org/10.1016/j.jval.2022.04.105

P301 Patient reported outcome measure for giant cell arteritis: Clinical testing (2022)
Journal Article
Almeida, C., Guly, C., Mackie, S., Bromhead, A., Stern, S., Dures, E., …Robson, J. C. (2022). P301 Patient reported outcome measure for giant cell arteritis: Clinical testing. Rheumatology, 61(Supplement_1), Article keac133.300. https://doi.org/10.1093/rheumatology/keac133.300

Background/Aims Giant cell arteritis (GCA) presents in people over 50, with headaches, visual involvement and large vessel vasculitis. A 30-item GCA-specific patient reported outcome measure (GCA PRO) was developed and tested in a clinical setting t... Read More about P301 Patient reported outcome measure for giant cell arteritis: Clinical testing.

OA23 Patient-reported outcome measure for giant cell arteritis: Cross-sectional validation study (2022)
Journal Article
Ndosi, M., Almeida, C., Dawson, J., Dures, E., Greenwood, R., Guly, C., …Robson, J. C. (2022). OA23 Patient-reported outcome measure for giant cell arteritis: Cross-sectional validation study. Rheumatology, 61(Supplement_1), https://doi.org/10.1093/rheumatology/keac132.023